POLB — Poolbeg Pharma Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.66 | ||
| Price to Tang. Book | 8.9 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -85.57% | ||
| Return on Equity | -58.55% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Poolbeg Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on the development of medicines to address unmet medical needs. Its clinical programmes target addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions, such as obesity with the development of an oral encapsulated glucagon-like peptide (GLP-1R) agonist. Its pipeline includes POLB 001 Oncology, POLB 001 Influenza, AI Programmes and Oral Encapsulated GLP-1programme. POLB 001 is an orally delivered p38 MAP Kinase inhibitor being developed for the prevention of CRS associated with Bispecific Antibodies and CAR T immunotherapy treatments in cancer. It uses artificial intelligence to identify infectious disease drug targets & treatments. The Oral Encapsulated GLP-1 programme leverages an advanced delivery system that encapsulates active pharmaceutical ingredients using Generally Regarded as Safe (GRAS) components.
Directors
- Cathal Friel CHM (62)
- Jeremy Skillington CEO (53)
- Ian Oconnell CFO (36)
- Eddie Gibson NID (50)
- Luke Oneill NID (60)
- Brendan Buckley NID (76)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- March 19th, 2021
- Public Since
- July 19th, 2021
- No. of Employees
- 15
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 763,437,106
- Address
- The Clubhouse Holborn, LONDON, EC4A 3AG
- Web
- https://www.poolbegpharma.com
- Phone
- +44 2071831499
- Auditors
- Gravita Audit Limited
Latest News for POLB
Upcoming Events for POLB
Poolbeg Pharma PLC at London Life Sciences Week
Poolbeg Pharma PLC at Mello Monday Webinar
Full Year 2026 Poolbeg Pharma PLC Earnings Release
Similar to POLB
4Basebio
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
Bioventix
London Stock Exchange
FAQ
As of Today at 12:43 UTC, shares in Poolbeg Pharma are trading at 5.85p. This share price information is delayed by 15 minutes.
Shares in Poolbeg Pharma last closed at 5.85p and the price had moved by +44.44% over the past 365 days. In terms of relative price strength the Poolbeg Pharma share price has outperformed the FTSE All Share Index by +28.34% over the past year.
The overall consensus recommendation for Poolbeg Pharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out morePoolbeg Pharma does not currently pay a dividend.
Poolbeg Pharma does not currently pay a dividend.
Poolbeg Pharma does not currently pay a dividend.
To buy shares in Poolbeg Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 5.85p, shares in Poolbeg Pharma had a market capitalisation of £44.66m.
Here are the trading details for Poolbeg Pharma:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: POLB
Based on an overall assessment of its quality, value and momentum Poolbeg Pharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Poolbeg Pharma is 19.00p. That is 224.79% above the last closing price of 5.85p.
Analysts covering Poolbeg Pharma currently have a consensus Earnings Per Share (EPS) forecast of -£0.01 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Poolbeg Pharma. Over the past six months, its share price has outperformed the FTSE All Share Index by +16.14%.
As of the last closing price of 5.85p, shares in Poolbeg Pharma were trading -5.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Poolbeg Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 5.85p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Poolbeg Pharma's management team is headed by:
- Cathal Friel - CHM
- Jeremy Skillington - CEO
- Ian Oconnell - CFO
- Eddie Gibson - NID
- Luke Oneill - NID
- Brendan Buckley - NID